Ferrari Marco, Mularoni Francesca, Smussi Davide, Gaudioso Piergiorgio, Bonomo Pierluigi, Friborg Jeppe, Ghi Maria Grazia, Gregoire Vincent, Harrington Kevin, Hunter Keith, Maroldi Roberto, Martino Rosemary, Mesia Ricard, Peretti Giorgio, Psyrri Amanda, Schindler Antonio, Succo Giovanni, Szturz Petr, Vilaseca Isabel, Nicolai Piero, Bossi Paolo
Section of Otorhinolaryngology-Head and Neck Surgery, Department of Neuroscience, University of Padova, Padova, Italy; Unit of Otorhinolaryngology-Head and Neck Surgery, Padua University Hospital, Padova, Italy; Guided Therapeutics Program International Scholarship, University Health Network, Toronto, ON, Canada.
Section of Otorhinolaryngology-Head and Neck Surgery, Department of Neuroscience, University of Padova, Padova, Italy.
Lancet Oncol. 2025 May;26(5):e264-e281. doi: 10.1016/S1470-2045(25)00020-8.
This Policy Review summarises an expert Delphi consensus process on larynx-preservation treatments in patients affected by intermediate-to-advanced laryngeal or hypopharyngeal squamous cell carcinoma. The experts, who represented all perspectives involved in multidisciplinary management of these patients and included patient representatives, approved 137 consensus statements that cover several relevant areas in the field of larynx-preserving treatments. Statements are grouped in the following topics: granular indications for T2-T3 cancer, indications for T4a cancer, indications for salvage organ-preservation surgery after chemoradiation failure, laryngeal function at baseline, which comorbidities are contraindications and to what extent, organ preservation in older patients: selection criteria, post-treatment surveillance, prognostic and predictive factors, listening to the patient's preferences: tools and implementation, prehabilitation and rehabilitation protocols, and cost-effectiveness of different laryngeal preservation approaches. We present a high-level summary of the results of the consensus process, with detailed reference to the full list of statements and supporting literature.
本政策审查总结了关于中晚期喉或下咽鳞状细胞癌患者保喉治疗的专家德尔菲共识过程。这些专家代表了参与这些患者多学科管理的所有观点,包括患者代表,批准了137项共识声明,涵盖了保喉治疗领域的几个相关领域。声明分为以下主题:T2 - T3癌症的具体适应症、T4a癌症的适应症、放化疗失败后挽救性器官保留手术的适应症、基线时的喉功能、哪些合并症是禁忌症以及禁忌程度如何、老年患者的器官保留:选择标准、治疗后监测、预后和预测因素、倾听患者偏好:工具与实施、术前康复和康复方案,以及不同保喉方法的成本效益。我们对共识过程的结果进行了高层次总结,并详细参考了声明完整列表及支持文献。